The “develOpment of metabolic and functional markers of Dementia IN Older people” (ODINO) Study: Rationale, Design and Methods

Abstract

Mild cognitive impairment (MCI), also termed mild neurocognitive disorder, includes a heterogeneous group of conditions characterized by declines in one or more cognitive domains greater than that expected during "normal" aging but not severe enough to impair functional abilities. MCI has been associated with an increased risk of developing dementia and even considered an early stage of it. Therefore, noninvasively accessible biomarkers of MCI are highly sought after for early identification of the condition. Systemic inflammation, metabolic perturbations, and declining physical performance have been described in people with MCI. However, whether biological and functional parameters differ across MCI neuropsychological subtypes is presently debated. Likewise, the predictive value of existing biomarkers toward MCI conversion into dementia is unclear. The "develOpment of metabolic and functional markers of Dementia IN Older people" (ODINO) study was conceived as a multi-dimensional investigation in which multi-marker discovery will be coupled with innovative statistical approaches to characterize patterns of systemic inflammation, metabolic perturbations, and physical performance in older adults with MCI. The ultimate aim of ODINO is to identify potential biomarkers specific for MCI subtypes and predictive of MCI conversion into Alzheimer's disease or other forms of dementia over a three-year follow-up. Here, we describe the rationale, design, and methods of ODINO.

Excessive sleep increased the risk of incidence of cognitive impairment among older Chinese adults: a cohort study based on the Chinese Longitudinal Healthy Longevity Survey (CLHLS)

“…The aging of the population is leading to an increasing burden of dementia and cognitive impairment (Picca et al, 2020). A clearer understanding of potentially modifiable determinants to enable the design of effective preventative interventions would be helpful in alleviating this increasing individual and societal burden.…”

The Role of Artificial Intelligence in Managing Multimorbidity and Cancer

“…PF&S was operationalized by our Geriatric Team in the context of the «Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies» (SPRINTT) project, one of the largest geriatric initiatives ever conducted in Europe [ 30 ]. SPRINTT was conceptualized to identify “real life” vulnerable older person at risk of mobility disability and to promote the implementation of successful ageing strategies across Europe through the adoption of personalized intervention protocols [ 31 ]. The key elements of the novel nosological entity of PF&S are the presence of a target organ damage (i.e., low skeletal muscle mass) and clinical manifestations pertaining to the physical function domain (i.e., weakness, slow walking speed, and poor balance), which can be objectively assessed using the Short Physical Performance Battery (SPPB) [ 32 ].…”

“…AGING: [ 16 , 17 , 27 , 28 ]. AGING and CANCER: [ 16 , 17 , 18 , 26 , 29 ]; MULTIMORBIDITY: [ 15 , 27 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 ]; AI SOLUTIONS: [ 20 , 21 , 42 , 43 , 44 , 45 , 46 , 47 , 48 ]. AGING and GYNECOLOGICAL CANCER: [ 13 , 49 , 50 , 51 , 52 , 53 , 54 ]; MULTIMORBIDITY: [ 22 , 23 , 25 , 49 , 50 , 53 , 55 , 56 ]; AI SOLUTIONS: [ 24 , 57 , 58 ].…”

Neuroimaging-Guided Transcranial Magnetic and Direct Current Stimulation in MCI: Toward an Individual, Effective and Disease-Modifying Treatment

“…Individuals with MCI exhibit greater cognitive compromise than that expected for their age and education level, without meeting the criteria widely employed for dementia. 11-13 Strikingly, individuals diagnosed with MCI, particularly the amnestic subtype, have a 10-fold greater risk of direct progression to AD or other types of dementia suggesting that the cognitive impairment in mild MCI is a probable prodromal phase of AD, indicating abnormal changes in neural structure. 10,13-15 Thus, according to some authors, MCI is equivalent to early stage AD.…”